S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought

Best Stocks Under $50.00 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $50.00 (50 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


JD Sports Fashion stock logo

#1 - JD Sports Fashion

OTCMKTS:JDSPY
Stock Price: $1.84 (-$0.11)
Average Trading Volume: 3,209 shares
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $205.83 (11,086.6% Upside)
JD Sports Fashion plc engages in the retail of branded sports fashion and outdoor clothing, footwear, accessories, and equipment for kids, women, and men. It operates through Sports Fashion and Outdoor segments. The company also retails leisure goods, sports goods, fishing gear, camping goods, boats, and bicycles, as well as distributes sports apparel and accessories, footwear, and apparel. It offers its products under the JD, Size?, Footpatrol, Finish Line, Shoe Palace, DTLR, Livestock, Sprinter, Sport Zone, Sizeer, JD Gyms, Tessuti, Scotts, Go Outdoors, Blacks, Millets, Tiso, Ultimate Outdoors, Fishing Republic, and Naylors brands. The company also operates online business. In addition, it licenses fashion brands and operates fitness centers; operates as online own label women's fashion retailer; and manufactures and distributes professional fitness equipment. The company has operations in the United Kingdom, Andorra, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Latvia, Lithuania, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Republic of Ireland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain and the Canary Islands, Sweden, Thailand, and the United Arab Emirates. The company was founded in 1981 and is headquartered in Bury, the United Kingdom. JD Sports Fashion plc is a subsidiary of Pentland Group Limited.
i3 Verticals stock logo

#2 - i3 Verticals

NASDAQ:IIIV
Stock Price: $23.66 (-$0.04)
PE Ratio: -62.26
Market Cap: $787.41 million
Average Trading Volume: 144,030 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $31.80 (34.4% Upside)
i3 Verticals, Inc. provides integrated payment and software solutions to small- and medium-sized businesses and organizations in education, non-profit, public sector, and healthcare markets in the United States. It operates in two segments, Merchant Services, and Proprietary Software and Payments. The company offers payment processing services that enables clients to accept electronic payments, facilitating the exchange of funds and transaction data between clients, financial institutions, and payment networks. The company also licenses software; and provides ongoing support, and other point of sale-related solutions. It offers its solutions to clients through direct sales force; distribution partners, including independent software vendors, value-added resellers, and independent sales organizations; and referral partners, such as financial institutions, trade associations, chambers of commerce, and card issuers. The company was founded in 2012 and is headquartered in Nashville, Tennessee.
Everi stock logo

#3 - Everi

NYSE:EVRI
Stock Price: $13.60 (+$0.25)
PE Ratio: 11.62
Market Cap: $1.20 billion
Average Trading Volume: 784,386 shares
P/E Ratio: 11.6
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.60 (66.2% Upside)
Everi Holdings Inc. develops and supplies entertaining game content, gaming machines, and gaming systems and services for land-based and iGaming operators in the United States, Canada, Australia, the United Kingdom, Europe, the Caribbean, Central America, and Asia. It operates in two segments, Games and Financial Technology Solutions. The company offers classic mechanical reel games and video reel games, as well as TournEvent of Champions, a national slot tournament; and sells gaming equipment and player terminals, licenses, game content, and ancillary equipment, such as signage and lighting packages. It also provides financial access services, such as funds dispensed and transmitted, credit card and POS debit card financial access transactions; check warranty; CashClub, a software payments platform that provides gaming operators with a personal computer workstation software user interface and point-of-sale terminal; CashClub Wallet, a digital payments platform for gaming operators; fully integrated kiosks that provide multiple functions to gaming operators on their casino floors; loyalty kiosk and related equipment; and other integrated kiosk solutions. In addition, the company offers non-funds dispensing terminals that perform authorizations for credit card financial access and POS debit card financial access transactions; and database services. Further, it provides Everi Compliance, a anti-money laundering management tool; Central Credit, a gaming patron credit bureau service; JackpotXpress, a jackpot payout and tax form management platform; and Loyalty platform, a software platform to adopt and deliver new promotional strategies, as well as support and maintenance services. It offers products for the casino, sports, entertainment, and hospitality industries. The company was formerly known as Global Cash Access Holdings, Inc. and changed its name to Everi Holdings Inc. in August 2015. Everi Holdings Inc. was founded in 1998 and is based in Las Vegas, Nevada.
Northland Power stock logo

#4 - Northland Power

OTCMKTS:NPIFF
Stock Price: $16.86 (-$1.23)
PE Ratio: -53.35
Average Trading Volume: 8,760 shares
Dividend Yield: 7.24%
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $50.75 (201.0% Upside)
Northland Power Inc., an independent power producer, develops, builds, owns, and operates clean and green power projects in North America, Europe, Latin America, and Asia. The company produces electricity from renewable resources, such as wind, solar, or hydropower, as well as clean-burning natural gas and biomass for sale under power purchase agreements and other revenue arrangements. It owned or had an economic interest in 3.2 gigawatts of operating generating capacity. The company was founded in 1987 and is headquartered in Toronto, Canada.
Mirum Pharmaceuticals stock logo

#5 - Mirum Pharmaceuticals

NASDAQ:MIRM
Stock Price: $26.52 (+$0.23)
PE Ratio: -5.58
Market Cap: $1.02 billion
Average Trading Volume: 489,309 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $49.00 (84.8% Upside)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
InflaRx stock logo

#6 - InflaRx

NASDAQ:IFRX
Stock Price: $3.78 (-$0.22)
PE Ratio: -4.85
Market Cap: $168.97 million
Average Trading Volume: 1.13 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (270.4% Upside)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Dyne Therapeutics stock logo

#7 - Dyne Therapeutics

NYSE:DYN
Stock Price: $10.99 (+$0.07)
PE Ratio: -3.23
Market Cap: $670.61 million
Average Trading Volume: 419,362 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $26.50 (141.1% Upside)
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Avidity Biosciences stock logo

#8 - Avidity Biosciences

NASDAQ:RNA
Stock Price: $8.87 (-$0.09)
PE Ratio: -2.86
Market Cap: $657.27 million
Average Trading Volume: 1.08 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $38.17 (330.3% Upside)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Harmonic stock logo

#9 - Harmonic

NASDAQ:HLIT
Stock Price: $10.45 (-$0.40)
PE Ratio: 58.06
Market Cap: $1.17 billion
Average Trading Volume: 1.49 million shares
P/E Ratio: 58.1
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.50 (77.0% Upside)
Harmonic Inc., together with its subsidiaries, provide video delivery software, products, system solutions, and services worldwide. The company operates in two segments, Video and Broadband. The Video segment sells video processing, production, and playout solutions and services to broadband operators, and satellite and telecommunications Pay-TV service providers, as well as to broadcast and media, including streaming media companies. This segment's video processing appliance solutions include network management and application software, and hardware products, such as encoders, video servers, high-density stream processing systems, and edge processors. This segment also provides software-as-a-service (SaaS) solutions, which enables the packaging and delivery of streaming services, including live streaming, video-on-demand, catch-up TV, start-over TV, network-DVR, and cloud-DVR services through HTTP streaming to various device along with dynamic and personal ad insertion. The Broadband segment offers CableOS software-based broadband access solutions; and CableOS central cloud services primarily to broadband operators. Its products enable customers to create, prepare, store, playout, and deliver a range of broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smart phones. The company also provides technical support and professional services, such as maintenance and support, consulting, implementation, program management, technical design and planning, building and site preparation, integration and equipment installation, end-to-end system testing, and training, as well as SaaS-related support and deployment. It sells its products through its direct sales force, as well as through independent resellers and systems integrators. Harmonic Inc. was incorporated in 1988 and is headquartered in San Jose, California.
89bio stock logo

#10 - 89bio

NASDAQ:ETNB
Stock Price: $16.63 (+$0.21)
PE Ratio: -7.88
Market Cap: $1.21 billion
Average Trading Volume: 1.64 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $37.63 (126.2% Upside)
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Energy Transfer stock logo

#11 - Energy Transfer

NYSE:ET
Stock Price: $12.76 (-$0.31)
PE Ratio: 10.63
Market Cap: $40.11 billion
Average Trading Volume: 11.46 million shares
P/E Ratio: 10.6
Dividend Yield: 9.64%
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.57 (29.9% Upside)
Energy Transfer LP provides energy-related services. The company owns and operates approximately 11,600 miles of natural gas transportation pipeline, and three natural gas storage facilities in Texas and two natural gas storage facilities located in the state of Texas and Oklahoma; and 19,945 miles of interstate natural gas pipeline. It also sells natural gas to electric utilities, independent power plants, local distribution and other marketing companies, and industrial end-users. The company owns and operates natural gas gathering and natural gas liquid (NGL) pipeline, processing plant, and treating and conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, Ohio, Oklahoma, Arkansas, Kansas, and Louisiana; natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas; and a natural gas gathering system in Ohio, as well as transport and supplies water to natural gas producer in Pennsylvania. It owns approximately 5,650 miles of NGL pipeline; NGL fractionation facilities; NGL storage facilities with working storage capacity of approximately 58 million barrels (MMBbls); and other NGL storage assets and terminal with an aggregate storage capacity of approximately 25 MMBbls. The company provides crude oil transportation, terminalling, acquisition, and marketing activities; and sells and distributes gasoline, middle distillate, and motor fuels and other petroleum product. It offers natural gas compression service; carbon dioxide and hydrogen sulfide removal service; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalty, and generate electrical power. The company was formerly known as Energy Transfer Equity, L.P. and changed its name to Energy Transfer LP in October 2018. Energy Transfer LP was founded in 1996 and is headquartered in Dallas, Texas.
Northern Oil and Gas stock logo

#12 - Northern Oil and Gas

NYSE:NOG
Stock Price: $42.02 (+$0.59)
PE Ratio: 2.95
Market Cap: $3.91 billion
Average Trading Volume: 1.60 million shares
P/E Ratio: 2.9
Dividend Yield: 3.52%
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $47.22 (12.4% Upside)
Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of crude oil and natural gas properties in the United States. It primarily holds interests in the Williston Basin, the Appalachian Basin, and the Permian Basin in the United States. The company is based in Minnetonka, Minnesota.
Atlas Energy Solutions stock logo

#13 - Atlas Energy Solutions

NYSE:AESI
Stock Price: $20.44 (+$0.20)
Market Cap: $2.04 billion
Average Trading Volume: 402,125 shares
Dividend Yield: 3.91%
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $24.70 (20.8% Upside)
Atlas Energy Solutions Inc. provides proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico. The company was founded in 2017 and is based in Austin, Texas.
CymaBay Therapeutics stock logo

#14 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $13.47 (+$0.51)
PE Ratio: -15.31
Market Cap: $1.31 billion
Average Trading Volume: 1.74 million shares
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.89 (25.4% Upside)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Xencor stock logo

#15 - Xencor

NASDAQ:XNCR
Stock Price: $23.32 (+$0.03)
PE Ratio: -10.90
Market Cap: $1.41 billion
Average Trading Volume: 338,023 shares
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $44.20 (89.5% Upside)
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Xenon Pharmaceuticals stock logo

#16 - Xenon Pharmaceuticals

NASDAQ:XENE
Stock Price: $37.70 (-$0.69)
PE Ratio: -15.14
Market Cap: $2.40 billion
Average Trading Volume: 377,385 shares
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $51.73 (37.2% Upside)
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Delta Air Lines stock logo

#17 - Delta Air Lines

NYSE:DAL
Stock Price: $44.17 (-$0.69)
PE Ratio: 9.52
Market Cap: $28.42 billion
Average Trading Volume: 10.67 million shares
P/E Ratio: 9.5
Dividend Yield: 0.91%
Consensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $56.88 (28.8% Upside)
Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its domestic network centered on core hubs in Atlanta, Minneapolis-St. Paul, Detroit, and Salt Lake City, as well as coastal hub positions in Boston, Los Angeles, New York-LaGuardia, New York-JFK, and Seattle; and international network centered on hubs and market presence in Amsterdam, Mexico City, London-Heathrow, Paris-Charles de Gaulle, and Seoul-Incheon. The company sells its tickets through various distribution channels, including delta.com and the Fly Delta app, reservations, online travel agencies, traditional brick and mortar, and other agencies. It also provides aircraft maintenance and engineering support, repair, and overhaul services; and vacation packages to third-party consumers, as well as aircraft charters, and management and programs. The company operates through a fleet of approximately 1,250 aircrafts. Delta Air Lines, Inc. was founded in 1924 and is based in Atlanta, Georgia.
Halliburton stock logo

#18 - Halliburton

NYSE:HAL
Stock Price: $40.70 (+$0.34)
PE Ratio: 14.96
Market Cap: $36.57 billion
Average Trading Volume: 9.37 million shares
P/E Ratio: 15.0
Dividend Yield: 1.57%
Consensus Rating: Buy (15 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $47.47 (16.6% Upside)
Halliburton Company provides products and services to the energy industry worldwide. It operates in two segments, Completion and Production, and Drilling and Evaluation. The Completion and Production segment offers production enhancement services that include stimulation and sand control services; cementing services, such as well bonding and casing, and casing equipment; completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, and service tools, as well as liner hanger, sand control, and multilateral systems; production solutions comprising coiled tubing, hydraulic workover units, downhole tools, and pumping and nitrogen services; and pipeline and process services, such as pre-commissioning, commissioning, maintenance, and decommissioning. This segment also provides electrical submersible pumps, as well as artificial lift services. The Drilling and Evaluation segment offers drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; oilfield completion, production, and downstream water and process treatment chemicals and services; drilling systems and services; wireline and perforating services consists of open-hole logging, and cased-hole and slickline; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. This segment also provides cloud based digital services and artificial intelligence solutions on an open architecture for subsurface insights, integrated well construction, and reservoir and production management; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and project management and integrated asset management services. Halliburton Company was founded in 1919 and is based in Houston, Texas.
Fidelity National Financial stock logo

#19 - Fidelity National Financial

NYSE:FNF
Stock Price: $42.11 (+$0.28)
PE Ratio: 22.28
Market Cap: $11.46 billion
Average Trading Volume: 1.42 million shares
P/E Ratio: 22.3
Dividend Yield: 4.27%
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $46.50 (10.4% Upside)
Fidelity National Financial, Inc., together with its subsidiaries, provides various insurance products in the United States. The company operates through Title, F&G, and Corporate and Other segments. It offers title insurance, escrow, and other title related services, including trust activities, trustee sales guarantees, recordings and reconveyances, and home warranty products. The company also provides technology and transaction services to the real estate and mortgage industries; and mortgage transaction services, including title-related services and facilitation of production and management of mortgage loans. In addition, it offers annuity and life insurance products, such as deferred and immediate annuities, as well as indexed universal life insurance products. Further, the company engages in the real estate brokerage business. Fidelity National Financial, Inc. is headquartered in Jacksonville, Florida.
ATI stock logo

#20 - ATI

NYSE:ATI
Stock Price: $43.26 (-$0.90)
PE Ratio: 22.18
Market Cap: $5.56 billion
Average Trading Volume: 1.24 million shares
P/E Ratio: 22.2
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $49.33 (14.0% Upside)
ATI Inc. manufactures and sells specialty materials and components worldwide. It operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.
Perrigo stock logo

#21 - Perrigo

NYSE:PRGO
Stock Price: $39.49 (+$0.99)
PE Ratio: -94.02
Market Cap: $5.35 billion
Average Trading Volume: 1.12 million shares
Dividend Yield: 2.77%
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $48.00 (21.5% Upside)
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in Ireland, the United States, France, Belgium, China, the United Kingdom, Germany, Switzerland, Austria, Italy, Australia, Greece, and Spain. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment develops, manufacture, and markets self-care products including upper respiratory, pain and sleep-aids, digestive health, nutrition, healthy lifestyle, skincare, women's health, and other products, as well as vitamins, minerals and supplements, and oral self-care in the United States and Canada. This segment offers its products under Burt's Bees, Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, and Steripod brands. Consumer Self-Care International segment comprises consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia, and store brand products in the United Kingdom and parts of Europe and Asia, which develops, manufactures, markets, and distributes consumer self-care brands through a network of drug and grocery store retailers, e-commerce stores, and para-pharmacies in more than 29 countries, primarily in Europe. In addition, the company offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
FTAI Aviation stock logo

#22 - FTAI Aviation

NYSE:FTAI
Stock Price: $34.95 (+$0.41)
PE Ratio: 53.77
Market Cap: $3.49 billion
Average Trading Volume: 1.12 million shares
P/E Ratio: 53.8
Dividend Yield: 3.43%
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $37.44 (7.1% Upside)
FTAI Aviation Ltd. owns and acquires infrastructure and related equipment for the transportation of goods and people worldwide. It operates through two segments, Aviation Leasing and Aerospace Products. The Aviation Leasing segment owns and manages aviation assets, including aircraft and aircraft engines, which it leases and sells to customers. As of December 31, 2022, this segment owned and managed 330 aviation assets consisting of 106 commercial aircraft and 224 engines, including four aircraft and one engine that were located in Ukraine, and eight aircraft and seventeen engines that were located in Russia. The Aerospace Products segment develops, manufactures, repairs, and sells aircraft engines and aftermarket components for aircraft engines. The company was founded in 2011 and is headquartered in New York, New York.
Community Healthcare Trust stock logo

#23 - Community Healthcare Trust

NYSE:CHCT
Stock Price: $34.45 (-$0.17)
PE Ratio: 107.66
Market Cap: $914.99 million
Average Trading Volume: 115,036 shares
P/E Ratio: 107.7
Dividend Yield: 5.25%
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $43.50 (26.3% Upside)
Community Healthcare Trust Incorporated is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in our target sub-markets throughout the United States. As of June 30, 2023, the Company had investments of approximately $991.2 million in 184 real estate properties (including a portion of one property accounted for as a sales-type lease and one property classified as held for sale). The properties are located in 34 states, totaling approximately 4.0 million square feet in the aggregate.
PROS stock logo

#24 - PROS

NYSE:PRO
Stock Price: $35.87 (+$0.47)
PE Ratio: -25.81
Market Cap: $1.66 billion
Average Trading Volume: 290,644 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $36.60 (2.0% Upside)
PROS Holdings, Inc. provides solutions that optimize the processes of selling and shopping in the digital economy worldwide. The company offers PROS Smart Configure Price Quote that improves sales productivity and accelerate deal velocity by automating common sales tasks; and PROS Smart Price Optimization and Management that enables businesses to optimize, personalize, and harmonize pricing across the complexity of their go-to-market channels in the context of dynamic market and competitive conditions. It also provides PROS Airline Revenue Optimization; PROS Airline Revenue Management solution that delivers algorithmic forecasting and network optimization for the travel industry; PROS Airline Real-Time Dynamic Pricing that offers accurate booking class availability and seat prices; PROS Airline Group Sales Optimizer, which enables airlines and their travel agent partners to create and manage group bookings, contracts, policies, and payments; and PROS Corporate Sales, a solution that enables airlines to create commercial agreements with their corporate customers. In addition, the company offers PROS Digital Retail, a configurable end-to-end solution for airlines to optimize the traveler experience from inspiration to post-trip; and PROS digital offer marketing solutions provide performance content management and search engine marketing tools that enable businesses in the travel industry. Further, it provides software-related services, such as implementation, configuration, consulting, training, maintenance, and support services. The company sells its software solutions to customers in various industries, including automotive and industrial manufacturing, transportation and logistics, chemicals and energy, food and beverage, healthcare, high tech, and travel. It markets and sells its software solutions through its sales force, as well as through partners, resellers, and systems integrators. The company was incorporated in 1985 and is headquartered in Houston, Texas.
Pure Storage stock logo

#25 - Pure Storage

NYSE:PSTG
Stock Price: $36.02 (-$0.45)
PE Ratio: 1,201.07
Market Cap: $11.08 billion
Average Trading Volume: 4.77 million shares
P/E Ratio: 1,201.1
Consensus Rating: Buy (12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $40.11 (11.4% Upside)
Pure Storage, Inc., together with its subsidiaries, provides data storage technologies, products, and services in the United States and internationally. The company's Purity software is shared across its products and provides enterprise-class data services, such as data reduction, data protection, and encryption, as well as storage protocols, including block, file, and object. Its products portfolio includes FlashArray for block-oriented storage, addressing databases, applications, virtual machines, and other traditional workloads; FlashArray//XL; and FlashArray//C, an all-QLC flash array. The company also provides FlashBlade, a solution for unstructured data workloads of various types; FlashStack that combines compute, network, and storage to provide an infrastructure platform; FlashRecover, an all-flash modern data protection solution; and AIRI, a full-stack AI-ready infrastructure. In addition, it offers evergreen storage subscription and Cloud Block Store, as well as Portworx a cloud-native Kubernetes data management solution It also offers technical and professional, training and education, and certification services. The company sells its products and subscription services through direct sales force and channel partners. The company was formerly known as OS76, Inc. and changed its name to Pure Storage, Inc. in January 2010. Pure Storage, Inc. was incorporated in 2009 and is headquartered in Mountain View, California.

More Stock Ideas from MarketBeat

My Account -